Celcuity (CELC) Stock May Be Overvalued After REVTORPYK Approval
Celcuity stock has delivered a very large 3 year return, yet its recent pullback and a mixed set of valuation checks raise questions about how much of the good news around its newly approved breast cancer therapy is already reflected in the price.
- Over the last 3 years Celcuity has returned roughly 7x, which sets a high bar for further gains given how much value has already been created for existing shareholders.
- The full FDA approval of REVTORPYK for advanced HR positive, HER2 negative breast cancer can support expectations for future revenue, but execution risks around the commercial launch and pricing may weigh on how investors value that opportunity.
- With a value score of 3 out of 6, Celcuity appears as a mixed picture rather than a clear bargain or clear overvaluation on the broader checks.
The issue now is whether Celcuity's current share price still leaves enough room for long term upside after such a strong run.
Is Celcuity Getting Expensive on Book Value?
P/B is often used for early stage biotechs like Celcuity because earnings and sales can be limited while the balance sheet and research assets carry most of the current value. For Celcuity, the current P/B of 80.5x stands far above both the Biotechs industry average of 2.6x and a peer average of 18.0x.
Despite the recent FDA approval of REVTORPYK raising interest in Celcuity, this gap suggests investors are paying a very high premium to the company’s stated book value. The model heavily penalises the stock for its risk profile and lack of positive free cash flow, so the implied fair P/B is far lower. It is best read as a warning signal that Celcuity screens as very expensive on this metric rather than as a precise target.
On balance, Celcuity stock appears overvalued on the current P/B multiple relative to both peers and the wider biotech industry.
See what the numbers say about this price — find out in our valuation breakdown.
The Celcuity Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Celcuity pick up where this valuation puzzle leaves off by spelling out which paths for Celcuity's growth, margins and earnings would need to play out for the stock to be worth materially more or materially less than it is today. Each narrative ties a fair value estimate to a particular mix of potential catalysts and risks, so you can see over time which version of Celcuity's story is actually unfolding.
One of the top community narratives on Celcuity: 39% undervalued
"This narrative explores a more pessimistic perspective on Celcuity compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts…"
Read one of the top narratives on Celcuity
Do you think there's more to the story for Celcuity? Head over to our Community to see what others are saying!
The Bottom Line
For Celcuity, the valuation picture tilts toward overvalued on traditional market multiples, with the extreme P/B premium doing most of the heavy lifting. The mixed value score underlines that this is not a clear-cut bargain, but a stock where expectations already assume a lot going right. From here, the key question is whether Celcuity can turn its newly approved therapy into a commercial track record that justifies those expectations, or whether the current premium leaves little margin for execution missteps.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com